Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study Comparing FDG-PET Versus MRI Based Target Volume Delineation in Glioblastoma and the Role of FDG-PET/CT in the Alteration of MRI Based Target Volumes.

NCT01083719 is registered in ClinicalTrials.gov with Medanta Institute of Clinical Research as lead sponsor.

NCT NCT01083719
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01083719 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study Comparing FDG-PET Versus MRI Based Target Volume Delineation in Glioblastoma and the Role of FDG-PET/CT in the Alteration of MRI Based Target Volumes.
Lead sponsor
Medanta Institute of Clinical Research
Phase
Phase 2
Overall status
Unknown status
Start date
April 30, 2010
Completion date
August 31, 2011
Enrollment
15 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma